10 Stocks Insiders Are Buying This Year

7. Ibio Inc (NYSEAMERICAN:IBIO)

Number of Insiders Buying: 7

Ibio is a biotech company focused on using AI and advanced computational biology to develop and design next-generation biopharmaceuticals for cardiometabolic diseases, obesity, cancer, and other hard-to-treat diseases. The company combines proprietary 3D modeling with innovative drug discovery platforms to create a pipeline of new antibody treatments to address various unmet needs.

For the second quarter ended Dec. 31, 2024, Ibio reported revenue of $200,000. Net loss amounted to $4.36 million, which compares to net loss of $4.49 million in the same period last year.

On January 7, Ibio, in collaboration with AstralBio Inc., announced the development of an antibody that inhibits the function of Activin E, a promising therapeutic target for cardiometabolic disorders and obesity using iBio’s patented Machine-Learning Antibody Engine.

Three days after the announcement, on January 10, seven insiders bought a total of around $654,995 worth of shares at a price of $2.72 per share. Among these insiders is the company’s chief financial officer, Felipe Duran, who acquired 9,191 shares worth nearly $25,000, increasing his holdings to 11,139 shares. It is possible that the management has a strong confidence in the development of an antibody that inhibits the function of Activin E, and therefore they decided to increase their holding and invest in the company.

Based on data from TipRanks, one Wall Street analyst has a Buy rating on the stock and a 12-month price forecast of $6. Moreover, three analysts have an average “Strong Buy” rating on Ibio stock, with a price target of $4.87, representing an increase of 41.98% from the latest price, reveals data from StockAnalysis.

As of February 14, 2025, IBIO has a market capitalization of approximately $33.87 million and an average trading volume of 340,448 shares. The stock is now trading at $3.43, having gained 40.00% year-to-date. Over the past 12 months, Ibio’s shares gained 172.22%.